Clinical Trial

A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 31, 2025 (before its estimated April 5, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-centre, single-arm, open-label, dose-escalation exploratory study with single-dose administration. Its objective is to evaluate the safety, tolerability, dose, anti-tumor efficacy, and pharmacokinetic characteristics of CG-105-12 in the participants with BCMA-positive relapsed/refractory multiple myeloma who previously received adequate but uneffective standard treatments.
Trial Details
NCT Number NCT06999031
Lead Sponsor The First Affiliated Hospital of Nanchang University
Collaborators: Cells & Genes Biotech (Shanghai) Co.,Ltd
Conditions Relapsed/Refractory, Multiple Myeloma
Enrollment 12 participants
Start Date 2024-09-05
Primary Completion 2026-04-05 (estimated)
Study Completion 2027-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-31